Gender differences in the development of experimental liver steatosis in laboratory rats

The aim. To study functional-morphological and biometric changes in the liver and lipid spectrum in an experiment in male and female laboratory rats when modeling fructose-induced liver steatosis. Materials and methods. The experimental study was conducted on 44 non-inbred sexually mature white rats, of which 20 were males aged 8-9 months with a body weight of 400-530 g. and 24 females aged 9-10 months with a body weight of 320-480 g. Modeling of liver steatosis was carried out for 28 days by adding fructose to drinking water throughout the experiment using 15%-th solution of fructose instead of drinking water. At the end of the experiment, body weight was measured, liver sampling for morphometric and histological studies and blood sampling for laboratory studies (transaminase, glucose and lipid spectrum levels) were performed. Results. When comparing body weight before the experiment and after its completion, a statistically significant increase in this indicator was found in females with experimental steatosis (p = 0.031), which indicates the formation of general obesity in them. The mass coefficient of the liver in the experimental groups of males and females with steatosis was significantly higher than in the controls (p= 0.009 and p = 0.009, respectively). During histological examination of liver tissue, the number of hepatocytes with steatosis in males and females in experimental models was significantly higher than in control groups and corresponded to the II-III degree of steatosis. A comparative analysis of the lipidogram parameters revealed that dyslipidemia developed during the formation of liver steatosis in animals of both groups with fructose-induced liver steatosis. Conclusion. In experimental modeling of fructose-induced liver steatosis in animals, regardless of gender, morphological changes in liver tissue are manifested by fatty dystrophy and hepatomegaly, dyslipidemia is registered. At the same time, males develop fermentemia, hyperglycemia without the formation of general obesity. In females, the course of experimental steatosis is accompanied by an increase in body weight without functional changes in the liver.

liver steatosis, experiment, dyslipidemia, obesity

1. Ivashkin V.T., Mayevskaya M. V., Pavlov Ch.S. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 2: 24-42. (in Russ.)@@ Ивашкин В. Т., Маевская М. В., Павлов Ч. С. и соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 2: 24-42.

2. Lazebnik L. B., Golovanova U. V., Turkina S. V. Non-alcoholic fatty liver disease in adults: clinic, diagnosis, treatment. Recommendations for therapists, the third version. Experimental and clinical gastroenterology. 2021; 185(1): 4-52. (in Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова У. В., Туркина С. В. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; 185(1): 4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.

3. Vinnitskaya E. V., Sandler Yu.G., Bordin D. S. A new paradigm of non-alcoholic fatty liver disease: phenotypic diversity of metabolically associated fatty liver disease. Effective pharmacotherapy. 2020; 16 (24): 54-63. (in Russ.) doi: 10.33978/2307-3586-2020-16-24-54-63.@@ Винницкая Е. В., Сандлер Ю. Г., Бордин Д. С. Новая парадигма неалкогольной жировой болезни печени: фенотипическое многообразие метаболически ассоциированной жировой болезни печени. Эффективная фармакотерапия. 2020; 16 (24): 54-63. doi: 10.33978/2307-3586-2020-16-24-54-63.

4. Rotonya M. C., Amanke О., Vandana К. Non-alcoholic fatty liver disease: Pathophysiology and management. MScGastroenterol Clin North Am. 2016; 45 (4):639-652. doi: 10.1016/j.gtc.2016.07.003.

5. Florentino G.S. de A., Cotrim Н. Р., Vilar С. Р. et al. Nonalcoholic fatty liver disease in menopausal women. Arq Gastroenterol. 2013; 50(3):180-185. doi: 10.1590/S0004-28032013000200032.

6. Younossi Z. M., Koenig А. В., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1):73-84. doi: 10.1002/hep.28431.

7. Bueverov A. O., Bogomolov P. O. Nonalcoholic fatty liver disease without obesity: a problem awaiting solution. Therapeutic Archive. 2017;89(12):226-232. (in Russ.) doi: 10.17116/terarkh20178912226-232.@@ Буеверов А. О., Богомолов П. О. Неалкогольная жировая болезнь печени без ожирения: проблема, ожидающая решения. Терапевтический архив. 2017;89(12): 226-232. doi: 10.17116/terarkh20178912226-232.

8. Chen H., Wang J., Li Z. et al. Consumption of Sugar-Sweetened Beverages Has a Dose-Dependent Effect on the Risk of Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Dose-Response Meta-Analysis.Int. J. Environ. Res. Public Health. 2019;16 (12):2192. doi: 10.3390/ijerph16122192.

9. Kim D., Chung G. E., Kwak M. S. et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14 (1): 132-138. doi: 10.1016/j.cgh.2015.07.024.

10. Koterov A. N., Ushenkova L. N., Zubenkova E. S. and others. The ratio of the ages of the main laboratory animals (mice, rats, hamsters, dogs) and humans: relevance to the problem of age-related radiosensitivity and analysis of published data. Medical radiology and radiation safety. 2018; 63(1):5-27. (in Russ.) doi: 10.1273/article_5a82e 4a3908213.56647014.@@ Котеров А. Н., Ушенкова Л. Н., Зубенкова Э. С. и др. Соотношение возрастов основных лабораторных животных (мышей, крыс, хомячков, собак) и человека: актуальность для проблемы возрастной радиочувствительности и анализ публикованных данных. Медицинская радиология и радиационная безопасность. 2018; 63 (1): 5-27. doi: 10.1273/article_5a82e 4a3908213.56647014.

11. Brus T. V. Modeling of non-alcoholic fatty liver disease of varying severity in laboratory rats and the possibility of its correction: abstract. dis. … Candidate of Medical Sciences: 14.03.03. SPb., 2018. 21 p. (in Russ.)@@ Брус Т. В. Моделирование неалкогольной жировой болезни печени различной степени тяжести у лабораторных крыс и возможности ее коррекции: автореф. дис. … канд. мед. наук: 14.03.03. СПб., 2018. 21 с.

12. Mayev I.V., Andreev D. N., Kucheryavy Yu.A., Dicheva D. T., Kuznetsova E. I. Nonalcoholic fatty liver disease from the standpoint of modern medicine. Moscow. Prima Print, 2020. 68 p. (in Russ.)@@ Маев И. В., Андреев Д. Н., Кучерявый Ю. А., Дичева Д. Т., Кузнецова Е. И. Неалкогольная жировая болезнь печени с позиций современной медицины. - М.: Прима Принт, 2020. - 68 с.

13. Brus T. V., Vasiliev A. G. Modern understanding of non-alcoholic fatty liver disease.Russian biomedical research. 2020; 5 (1): 18-25. (in Russ.)@@ Брус Т. В., Васильев А. Г. Современное представление о неалкогольной жировой болезни печени. Российские биомедицинские исследования. 2020; 5 (1): 18-25.

14. DiStefano J. K., Shaibi G. Q. The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. Pediatr Obes. 2020;16 (6): doi: 10.1111/ijpo.12759.

15. Ribeiro A., Igual-Perez M. J., Santos Silva Е., Sokal Е. М. Childhood fructoholism and fructoholic liver disease. Hepatol Commun. 2018; 3 (1):44-51. doi: 10.1002/hep4.1291.

16. Toop C. R., Gentili S. Fructose Beverage Consumption Induces a Metabolic Syndrome Phenotype in the Rat: A Systematic Review and Meta-Analysis. Nutrients. 2016; 8(9): 577. doi:10.3390/nu8090577.

17. Mock K., Lateef S., Benedito V. A., Tou J. C. High-fructose corn syrup-55 consumption alters hepatic lipid metabolism and promotes triglyceride accumulation. J. Nutr. Biochem. 2017;39:32-39. doi: 10.1016/j.jnutbio.2016.09.010.

18. Gulyaeva I.L., Bulatova I. A., Sobol A. A. Pathogenetic justification of the use of a biologically active food additive containing fulvic acid and folate for the prevention of non-alcoholic liver steatosis (experimental study). Medical science and education of the Urals. 2023; 24(2):97-104. (in Russ.) doi: 10.36361/ 18148999_2023_24_2_97.@@ Гуляева И. Л., Булатова И. А., Соболь А. А. Патогенетическое обоснование применения биологически активной пищевой добавки, содержащей фульвовую кислоту и фолат для профилактики неалкогольного стеатоза печени (экспериментальное исследование). Медицинская наука и образование Урала. 2023;24(2):97-104. doi: 10.36361/18148999_2023_24_2_97.

19. Andres-Hernando A., Orlicky D. J., Kuwabara М. Deletion of Fructokinase in the Liver or in the Intestine Reveals Differential Effects on Sugar-Induced Metabolic Dysfunction. Cell Metab. 2020; 32 (1): 117-127.e3. doi: 10.1016/j.cmet.2020.05.012.